[CAS NO. 1491917-83-9] Sacituzumabgovitecan

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1491917-83-9]

Catalog

HY-132254

Brand

MCE

CAS

1491917-83-9

DESCRIPTION [1491917-83-9]

Overview

MDL	-
Molecular Weight	489.57
Molecular Formula	C₂₅H₃₁N₉O₂
SMILES	[Sacituzumab govitecan]

For research use only. We do not sell to patients.

Summary

Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. Sacituzumab govitecan shows anticancer activity ^[1] .

In Vivo

Sacituzumab govitecan (IMMU-132) (17.5 mg/kg; twice weekly for 4 weeks) results in significant anti-tumor effects in mice bearing human gastric cancer xenografts ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT04230109	Aditya Bardia\|Gilead Sciences\|Massachusetts General Hospital	Invasive Breast Cancer\|Triple Negative Breast Cancer\|ER-Negative Breast Cancer\|PR-Negative Breast Cancer\|HER2-negative Breast Cancer	July 7, 2020	Phase 2
NCT05609968	Merck Sharp & Dohme LLC\|Gilead Sciences	Carcinoma, Non-Small-Cell Lung	December 16, 2022	Phase 3
NCT04039230	Massachusetts General Hospital\|Pfizer	Breast Cancer	October 9, 2019	Phase 1\|Phase 2
NCT03337698	Hoffmann-La Roche	Carcinoma, Non-Small-Cell Lung	January 2, 2018	Phase 1\|Phase 2
NCT04958785	Gilead Sciences	Triple-Negative Breast Cancer	December 14, 2021	Phase 2
NCT03725761	University of Wisconsin, Madison\|National Cancer Institute (NCI)\|Gilead Sciences	Prostate Cancer	October 24, 2018	Phase 2
NCT05581589	University of Washington\|Gilead Sciences	Muscle Invasive Bladder Carcinoma\|Stage II Bladder Cancer AJCC v8\|Stage IIIA Bladder Cancer AJCC v8	November 2022	Phase 2
NCT03424005	Hoffmann-La Roche\|Seagen Inc.\|Gilead Sciences	Triple Negative Breast Cancer	April 2, 2018	Phase 1\|Phase 2
NCT04251416	Alessandro Santin\|Gilead Sciences\|Yale University	Endometrial Carcinoma	February 25, 2020	Phase 2
NCT03971409	Hope Rugo, MD\|Translational Breast Cancer Research Consortium\|Hoosier Cancer Research Network\|Array BioPharma\|Pfizer\|Breast Cancer Research Foundation\|Johns Hopkins University\|University of California, San Francisco	Stage III Breast Cancer\|Stage IIIA Breast Cancer\|Stage IIIB Breast Cancer\|Stage IIIC Breast Cancer\|Stage IV Breast Cancer\|Invasive Breast Carcinoma\|Recurrent Breast Carcinoma\|Triple-Negative Breast Carcinoma\|Unresectable Breast Carcinoma	July 8, 2019	Phase 2
NCT04639986	Everest Medicines\|Iqvia Pty Ltd\|Medidata Solutions\|Parexel	Metastatic Breast Cancer	November 23, 2020	Phase 3
NCT02161679	Gilead Sciences	Triple-negative Breast Cancer	August 2016	Phase 2
NCT04826341	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	HRD Cancer\|SCLC\|Advanced Solid Tumors	September 20, 2021	Phase 1\|Phase 2
NCT04448886	Ana C Garrido-Castro\|Merck Sharp & Dohme LLC\|Gilead Sciences\|Dana-Farber Cancer Institute	Invasive Breast Cancer\|Metastatic Breast Cancer\|HR-Positive Breast Cancer\|HER2-negative Breast Cancer	September 23, 2020	Phase 2
NCT04434040	Dana-Farber Cancer Institute\|Genentech, Inc.\|Stand Up To Cancer	Breast Cancer\|Triple Negative Breast Cancer\|Residual Cancer\|Circulating Tumor DNA	July 2, 2020	Phase 2
NCT05552001	UNICANCER\|Gilead Sciences	Triple Negative Breast Cancer\|Metastatic Breast Cancer	January 1, 2023	Phase 3
NCT03992131	Clovis Oncology, Inc.\|Gilead Sciences	Ovarian Cancer\|Triple-negative Breast Cancer\|Urothelial Carcinoma\|Solid Tumor	June 28, 2019	Phase 1\|Phase 2
NCT04454437	Everest Medicines\|IQVIA RDS (Shanghai) Co., Ltd.\|Medidata Solutions\|Q Squared Solutions (Beijing) Co., Ltd\|Parexel	Metastatic Triple-negative Breast Cancer	October 23, 2020	Phase 2
NCT03869190	Hoffmann-La Roche\|Gilead Sciences, Inc., GlaxoSmithKline plc, Seattle Genetics and Astellas	Urothelial Carcinoma\|Bladder Cancer	June 1, 2019	Phase 1\|Phase 2
NCT04320693	Gilead Sciences	Metastatic Triple-Negative Breast Carcinoma
NCT04863885	H. Lee Moffitt Cancer Center and Research Institute\|Bristol-Myers Squibb\|Gilead Sciences	Metastatic Urothelial Carcinoma	April 30, 2021	Phase 1\|Phase 2
NCT05520723	MedSIR\|Gilead Sciences	Triple Negative Breast Cancer\|Breast Cancer	January 11, 2023	Phase 2
NCT05327530	EMD Serono Research & Development Institute, Inc.\|Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics\|EMD Serono	Locally Advanced or Metastatic Urothelial Carcinoma	August 17, 2022	Phase 2
NCT04468061	Dana-Farber Cancer Institute\|Gilead Sciences\|Merck Sharp & Dohme LLC	Breast Cancer\|Triple Negative Breast Cancer\|PD-L1 Negative	July 20, 2020	Phase 2
NCT05226117	IRCCS San Raffaele\|High Research	Urothelial Carcinoma	November 29, 2021	Phase 2
NCT04559230	The University of Texas Health Science Center at San Antonio	Glioblastoma	January 6, 2022	Phase 2
NCT04595565	German Breast Group\|Gilead Sciences\|Austrian Breast & Colorectal Cancer Study Group\|Spanish Breast Cancer Research Group (GEICAM)\|ETOP IBCSG Partners Foundation\|Cancer Trials Ireland\|UNICANCER	HER2-negative Breast Cancer\|Triple Negative Breast Cancer	October 28, 2020	Phase 3
NCT04647916	Southwest Oncology Group\|National Cancer Institute (NCI)\|Gilead Sciences	Anatomic Stage IV Breast Cancer AJCC v8\|Invasive Breast Carcinoma\|Metastatic HER2 Negative Breast Carcinoma\|Metastatic Malignant Neoplasm in the Brain\|Prognostic Stage IV Breast Cancer AJCC v8	December 15, 2020	Phase 2
NCT05143229	University of Kansas Medical Center\|Novartis Pharmaceuticals\|Gilead Sciences	Breast Cancer	March 28, 2022	Phase 1
NCT04986579	Dana-Farber Cancer Institute\|Paxman Coolers Limited\|AstraZeneca\|Eisai Inc.\|Daiichi Sankyo, Inc.\|Gilead Sciences	Metastatic Breast Cancer\|Chemotherapy-induced Alopecia	October 7, 2021	Phase 2
NCT03995706	The University of Texas Health Science Center at San Antonio\|Gilead Sciences	Glioblastoma	July 17, 2019	Early Phase 1
NCT05332561	German Cancer Research Center	Early-stage Breast Cancer	December 2022	Phase 2
NCT04724018	Dana-Farber Cancer Institute\|Gilead Sciences	Urothelial Cancer\|Metastatic Urothelial Carcinoma\|Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter\|Bladder Cancer	May 20, 2021	Phase 1
NCT02574455	Gilead Sciences	Breast Cancer	November 7, 2017	Phase 3

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Store at 4°C, do not freeze